{"filings":[{"id":78322,"accession_number":"0001104659-26-060747","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2026-05-14T12:50:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.","Cash $13.2M provides runway into Q4 2026; closed $12.5M of a $26.9M financing in Jan 2026.","Halneuron Phase 2b in CINP: 164 enrolled, top-line results expected fall 2026.","SP16 IND approved; Phase 1b in CIPPN funded by NCI, enrollment starts mid-2026.","Announced global partnership for legacy antiviral assets with potential value up to $100M to Dogwood and shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109048,"accession_number":"0001104659-26-034928","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.","Raised $12.5M in Q1 2026; combined with year-end cash extends runway through data release.","Filed IND for SP16 IV (chemo-induced neuropathy); Phase 1b fully funded by NCI grant.","Advanced synthetic Halneuron formulation for Phase 3; aims to cut costs and boost yields."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109047,"accession_number":"0001104659-26-029992","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).","Cash $6.5M at Dec 31, 2025; Jan 2026 financing raised $11.4M net to fund through Phase 2b readout.","Halneuron CINP Phase 2b >50% enrolled; interim analysis showed separation from placebo; top-line expected Q3 2026.","R&D expenses FY 2025 $21.8M (up from $3.5M) due to $12.0M SP16 license fee and clinical trial costs.","G&A expenses fell to $6.1M from $8.7M due to lower nonrecurring transaction costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109046,"accession_number":"0001104659-26-027090","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Dogwood Therapeutics shareholders approve warrant exercise for up to 4.4M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal to approve potential exercise of warrant for 4,386,037 shares passed with 29,286,786 votes for, 19,057 against, 4,466 abstentions.","Approval required under Securities Purchase Agreement dated Jan 11, 2026 and Nasdaq Listing Rule 5635(d).","Adjournment proposal also approved with 29,283,790 for, 21,571 against.","Quorum of 29,310,309 shares (88.03% of voting power) present at Special Meeting held March 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109045,"accession_number":"0001104659-26-004838","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.","Licensed SP16 IV (royalty-free, global) for cancer neuropathy; Phase 1b fully funded by NCI development grant.","Developed chemically equivalent synthetic Halneuron for Phase 3; new IP if granted extends protection to 2046.","Milestones: final Phase 2b data Q3 2026, SP16 IND filing Q1 2026, dosing Phase 1b by mid-2026.","Completed January financing (undisclosed amount) to fund pipeline; end-of-Phase 2 FDA submission targeted late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109044,"accession_number":"0001104659-26-003211","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics raises $12.5M upfront; potential $14.4M from warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $12.5M from registered direct offering and concurrent private placement; potential additional $14.4M upon warrant exercise.","Offering priced at-the-market under Nasdaq rules: $2.85 per unit (share or pre-funded warrant plus Common Stock warrant).","Warrants exercisable at $3.28 per share, subject to stockholder approval, expire 5.5 years after approval.","Company terminated Northland at-the-market agreement; only $89,792 raised under that facility.","Proceeds to advance Halneuron Phase 2b final data readout and pursue strategic opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125512,"accession_number":"0001104659-25-116865","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["1.01","10.1","9.01"],"status":"ready","headline":"Dogwood Therapeutics enters ATM equity distribution agreement to sell up to $8.6M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Northland Securities to sell up to $8,558,712 of common stock via at-the-market offerings.","Amount represents 21.38% of the value of outstanding common stock held by non-affiliates.","Sales agent commission: 3.0% of gross proceeds from shares sold under the agreement.","Shares will be issued under effective shelf registration (File No. 333-287575) and a prospectus supplement dated Nov 28, 2025.","Agreement includes customary representations, warranties, indemnification, and termination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125511,"accession_number":"0001104659-25-114919","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Dogwood Therapeutics completes business combination with Sealbond; approves equity plan adding 2.78M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the potential issuance of common stock upon conversion of Series A, A-1, and A-2 preferred stock.","Business combination with Sealbond Limited (per Share Exchange Agreement dated Oct 7, 2024) is now complete.","Second Amended and Restated Equity Incentive Plan approved, increasing reserved shares from 191,122 to 2,972,787.","Special meeting quorum: 820,239 shares (35.76% of voting power) as of Oct 14, 2025 record date.","All five proposals passed with >772K votes for, including adjournment and plan approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125510,"accession_number":"0001104659-25-107471","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.","100 patients enrolled, 80 completed in Halneuron Phase 2b trial; interim analysis on track for Q4 2025.","Secured exclusive worldwide royalty-free license to develop SP16 for cancer-related pain via all-stock transaction.","Cash and equivalents of $10.1M expected to fund operations into Q1 2026.","SP16 Phase 1b study fully funded by National Cancer Institute; FDA feedback anticipated."],"consensus_eps_estimate":-1.2495,"consensus_eps_actual":-18.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125509,"accession_number":"0001104659-25-098360","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics posts Q4 2025 update presentation; no specific data in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed as Exhibit 99.1 highlights first-in-class therapies for cancer neuropathy.","No financial results, clinical data, or guidance changes included in the provided excerpt.","Filed as Regulation FD disclosure; presentation may be used with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142249,"accession_number":"0001104659-25-094109","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).","Consideration: 382,034 common shares + 179.1878 Series A-2 Preferred shares (convert 1:10,000), representing 7.31% fully diluted.","Phase 1b CIPN study fully funded by NCI; patient enrollment projected first half 2026.","Halneuron Phase 2b ongoing (80 patients randomized); interim data from 90-100 patients expected December 2025.","Support agreements with Serpin, Tungsten, and Sealbond to vote for stockholder approval of preferred stock conversions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142248,"accession_number":"0001558370-25-011311","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.","R&D expenses $2.5M (up from $0.3M) driven by clinical trial costs; G&A $1.3M (up from $0.7M).","Net loss $3.8M ($1.99 per share) vs $1.0M ($1.15) in Q2 2024; no revenue reported.","Cash $13.4M expected to fund operations through Q1 2026; Halneuron fast-tracked by FDA.","IMC-1 (fibromyalgia) ready for Phase 3; IMC-2 (Long-COVID) paused due to government funding uncertainty."],"consensus_eps_estimate":-1.938,"consensus_eps_actual":-9.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142247,"accession_number":"0001558370-25-009060","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dogwood Therapeutics increases CFO Angela Walsh's base salary to $321,903","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved CFO salary increase from $279,916 to $321,903 per year.","Increase effective July 1, 2025, based on peer company compensation review.","Ms. Walsh remains CFO, Corporate Secretary and Treasurer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160261,"accession_number":"0001558370-25-008817","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 108,612-share increase to Dogwood equity incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan amendment raises shares reserved from 82,500 to 191,112; approved with 275,020 for, 6,482 against, 1,284 abstain.","Seven directors elected: De La Rosa, Duncan, Keefer, Thomas, Toh, Whitley, Yu. No director changes announced.","Ratification of Forvis Mazars as auditor for FY2025: 888,808 for, 31,671 against, 1,116 abstain.","Annual meeting quorum: 921,595 shares (48.22% voting power).","Amendment includes one-year minimum vesting for future grants, with limited exception for new hires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160260,"accession_number":"0001558370-25-006866","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.","Halneuron Phase 2b CINP study initiated; interim data readout expected Q4 2025.","$19.5M loan from CK Life Sciences affiliate converted to equity; $4.8M gross common stock raise.","Cash and equivalents of $17.5M provides operational runway through Q1 2026.","Regained Nasdaq compliance with minimum stockholders' equity of $2.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160259,"accession_number":"0001558370-25-004362","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics regains Nasdaq minimum equity compliance after $19.9M debt swap and $4.8M offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq minimum stockholders' equity requirement ($2.5M).","Debt exchange with Conjoint canceled ~$19.9M debt for Series A-1 preferred stock.","Stock offering raised ~$4.8M gross proceeds from institutional investors.","Cash position $17.5M as of Q1 2025, no debt.","Shares outstanding: 1,911,128 as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178556,"accession_number":"0001558370-25-004150","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Therapeutics Q4 2024 net loss $8.2M; cash $14.8M; Halneuron Phase 2b interim data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).","Cash $14.8M at Dec 31, 2024; $4.8M capital raise and conversion of $19.5M debt to equity extend runway through Q1 2026.","Halneuron Phase 2b CINP trial dosing commenced; interim data readout expected Q4 2025.","Largest shareholder converted $19.5M loan to equity, strengthening balance sheet.","Exploring partnerships for IMC-2 (Long-COVID) and IMC-1 (fibromyalgia); update on IMC-1 expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178555,"accession_number":"0001558370-25-002978","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.","Proceeds to advance Halneuron clinical development and for working capital.","Offering closed March 14, 2025; Maxim Group LLC acted as sole placement agent.","Company expects cash runway through Q1 2026; Halneuron Phase 2b CINP interim data planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178554,"accession_number":"0001558370-25-002750","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Dogwood converts $19.9M debt and interest to Series A-1 preferred equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$19.5M principal plus accrued interest ($19,926,891 total) exchanged for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.","Each preferred share convertible into 10,000 common shares, pending stockholder approval and Nasdaq rules.","All existing debt removed from balance sheet; company funded through Q4 2025 interim of Phase 2b CINP trial.","Largest shareholder CK Life Sciences (through Conjoint) facilitated the conversion, signaling confidence in Halneuron program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195220,"accession_number":"0001558370-24-016346","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K/A","filed_at":"2024-12-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Pharmagesic financials: $4.9M loss, $82M deficit; Dogwood provides $19.5M funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pharmagesic (Holdings) Inc. (acquired Oct 7) had $4.9M net loss in 2023; no revenue; R&D costs $3.9M.","As of Dec 2023, stockholders' deficit was $78.7M, accumulated deficit $82.0M; total liabilities $65.1M.","Post-Dec 2023, $63.4M due to fellow subsidiaries settled; $36.0M preferred shares exchanged for common.","Dogwood secured $19.5M loan from CK Life Sciences to fund Pharmagesic operations through early 2026.","Halneuron (tetrodotoxin) is the lead candidate for chemotherapy-induced neuropathic pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195223,"accession_number":"0001558370-24-015884","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dogwood Therapeutics receives Nasdaq delisting notice for low stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity fell below $2.5M minimum per Q3 2024 10-Q; delisting risk under Nasdaq Rule 5550(b)(1).","Company has until December 30, 2024 to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Acquisition of Pharmagesic closed Oct 7, 2024, after the Q3 report, not reflected in equity calculation.","No immediate effect on listing; common stock (DWTX) continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195222,"accession_number":"0001558370-24-014749","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.","Cash $2.0M at Sep 30; $16.5M loan from CKLS affiliate received Oct 7; $3M tranche needed Feb 2025 to fund through 2025.","Top-line results from IMC-2 Long-COVID Phase 2a study expected mid-November 2024.","Halneuron Phase 2b CINP interim data expected 2H 2025; FDA fast-track designation granted.","Company formed via combination of Virios and Pharmagesic; pipeline includes IMC-1, IMC-2, and Halneuron."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195221,"accession_number":"0001558370-24-013889","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.","Top-line results from phase 2a study of IMC-2 for Long-COVID expected mid-November 2024.","Integration of Pharmagesic (Holdings) Inc. acquisition (closed early Oct 2024) ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195224,"accession_number":"0001558370-24-013167","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Virios acquires Pharmagesic, receives $19.5M loan, appoints new board, changes name to Dogwood Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.","Received $19.5M loan from CKLS affiliate; $16.5M funded at close, $3M due Feb 2025.","Existing shareholders get CVR entitling to 87.75% of future Halneuron milestone payments over 7 years.","Board: Richard Burch resigned; Alan Yu and Melvin Toh (CKLS) appointed; Angela Walsh promoted to CFO.","Name change to Dogwood Therapeutics; stockholder meeting required for conversion and reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211479,"accession_number":"0001558370-24-011486","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Virios Q2 net loss $1.0M; Long-COVID Phase 2a data expected Oct 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.0M ($0.05/sh) vs $1.4M ($0.08/sh) in Q2 2023; revenue was $0.","Cash $3.0M at June 30, 2024; expects runway into Q1 2025 after $1.7M public offering.","Enrollment completed in Long-COVID Phase 2a (valacyclovir/celecoxib vs placebo); top-line data October 2024.","R&D expense fell to $0.3M from $0.6M; G&A fell to $0.7M from $0.9M, both YoY.","Blinded safety analysis shows no serious adverse events; study drug well tolerated to date."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230137,"accession_number":"0001558370-24-009327","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Virios Therapeutics annual meeting elects all six director nominees, ratifies FORVIS as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 8,699,494 shares (45.17% of voting power) present at June 18, 2024 meeting.","All six director nominees elected: Burch (3,201,273 for), De La Rosa (2,440,247), Duncan (3,183,237), Keefer (3,198,840), Thomas (3,201,528), Whitley (1,964,627).","Highest withheld votes were for Dr. Whitley with 1,442,138 withheld.","Ratification of FORVIS LLP as auditor for FY2024 approved with 8,347,686 for, 241,056 against, 110,752 abstain.","No broker non-votes on auditor ratification; broker non-votes of 5,292,729 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230136,"accession_number":"0001558370-24-009066","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Virios Therapeutics granted Nasdaq exception until Oct 28, 2024 to regain $1.00 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearing Panel grants exception until October 28, 2024 to meet minimum $1.00 bid price rule.","If not compliant by October 11, 2024, Company must pursue a reverse stock split by the deadline.","Failure to regain compliance by October 28, 2024 will result in delisting from Nasdaq Capital Market.","Initial deficiency notice was received November 7, 2023; prior 180-day cure period expired April 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230135,"accession_number":"0001558370-24-008450","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Virios Therapeutics prices $1.7M public offering of 8.5M shares at $0.20/share for Long-COVID study prep","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 8,500,000 shares at $0.20 per share for gross proceeds of approx. $1.7M.","Net proceeds to fund preparatory activities for planned IMC-2 Long-COVID Phase 2b study and general corporate purposes.","Offering expected to close on May 22, 2024; Maxim Group LLC acting as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230134,"accession_number":"0001558370-24-007474","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.","R&D expenses $0.3M (down from $0.5M); G&A expenses $1.0M (down from $1.1M).","BHC Long-COVID phase 2 trial (IMC-2) exceeded 50% enrollment; top-line data expected H2 2024.","Preliminary safety shows IMC-2 well tolerated; no serious adverse events reported to date.","Global patent for IMC-2 covering Long-COVID and Alzheimer's published; FM partner discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230133,"accession_number":"0001558370-24-007096","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Virios receives Nasdaq deficiency notice for bid price; requests hearing to seek compliance extension","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Second Nasdaq letter received May 1, 2024 for failure to maintain $1.00 minimum bid price.","Initial 180-day compliance period expired April 30, 2024; company has requested a hearing to stay delisting.","Plan to regain compliance includes IMC-2 Long-COVID study data from Bateman Horne Center and potential reverse stock split.","Hearing before Nasdaq panel will determine extension; common stock (VIRI) remains listed pending decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248561,"accession_number":"0001558370-24-002613","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Virios shareholders approve reverse stock split at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held March 1, 2024; quorum 64.58% of shares outstanding.","Proposal 1 (reverse stock split) approved with 7,553,703 For vs 4,697,955 Against.","Proposal 2 (adjournment to solicit proxies) approved with 7,778,383 For vs 4,484,974 Against.","No broker non-votes; both proposals passed by required vote.","Reverse split effective date and ratio not disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248560,"accession_number":"0001558370-24-002113","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.","R&D expenses $1.7M in FY2023 vs $8.1M in FY2022, driven by lower clinical trial costs.","Cash at Dec 31, 2023: $3.3M; expected to fund operations into Q4 2024.","FDA agreed to use fatigue as primary endpoint for IMC-2 Phase 2 in Long-COVID; initiation targeted H2 2024, pending funding.","Placebo-controlled data on valacyclovir/celecoxib for Long-COVID from Bateman Horne Center expected summer 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248559,"accession_number":"0001558370-24-001840","cik":1818844,"company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Virios Therapeutics cuts cash compensation 10%; grants stock options to officers and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 10% salary reduction for all employees including executive officers, effective March 1, 2024.","Non-employee director cash compensation also reduced by 10%.","Stock options granted to executive officers and directors: CEO Greg Duncan receives 138,835 options; total 410,570 options across 10 recipients.","Options have exercise price of $0.357/share and vest on February 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":56289150.08888888,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}